SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Deng H, Liu R, Ellmeier W et al. Identification of a major co- receptor for primary isolates of HIV-1. Nature 1996; 381: 6616.
  • 2
    Dragic T, Litwin V, Allaway GP et al. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature 1996; 381: 66773.
  • 3
    Amara A, Gall SL, Schwarts O et al. HIV coreceptor downregulation as antiviral principle: SDF-1α-dependent internalization of the chemokine receptor CXCR4 contributes to inhibition of HIV replication. J Exp Med 1997; 186: 13946.
  • 4
    Lehner T, Wang Y, Cranage M et al. Upregulation of β-chemokines and downmodulation of CCR5 coreceptors inhibit simian immunodeficiency virus transmission in non-human primates. Immunology 2000; 99: 56977.
  • 5
    Lehner T, Wang Y, Bravery CA et al. Antibodies to CCR5 receptors and b-chemokines, generated by xenogeneic immunization, in the prevention of SIV infection in macaques. National Cooperative Vaccine Development Grant Meeting,: Bethesda: NIH, May 1997.
  • 6
    Lehner T, Wang Y, Doyle C et al. Induction of inhibitory antibodies to the CCR5 chemokine receptor and their complementary role in preventing SIV infection in macaques. Eur J Immunol 1999; 29: 242735.
  • 7
    Lehner T, Doyle C, Wang Y et al. Immunogenicity of the extracellular domains of the CC chemokine receptor 5 and the effects of SIV or HIV infectivity. J Immunol 2001; 166: 744655.
  • 8
    Zuber B, Hinkula J, Vadros D et al. Induction of immune responses and break of tolerance by DNA against the HIV-1 coreceptor CCR5 but no protection from SIVsm challenge. Virology 2000; 278: 40011.
  • 9
    Lopalco L, Barassi C, Pastori C et al. CCR5-reactive antibodies in seronegative partners of HIV-seropositive individuals down-modulate surface CCR5 in vivo and neutralize the infectivity of R5 strains of HIV-1 in vivo. J Immunol 2000; 164: 342633.
  • 10
    Ditzel HJ, Rosenkilde MM, Garred P et al. The CCR5 receptor acts as an alloantigen in CCR5 delta 32 homozyqous individuals: identification of chemokines and HIV-1-blocking human antibodies. Proc Natl Acad Sci USA 1998; 95: 52415.
  • 11
    Paxton WA, Martin SR, Tse D et al. Relative resistant to HIV-1 infection of CD4 lymphocytes from persons who remain uninfected despite multiple high-risk sexual exposures. Nature (Med) 1996; 2: 4127.
  • 12
    Liu R, Paxton WA, Choe S et al. Homozygous defect in HIV-1 co-receptor accounts for resistance of some multiply-exposed individuals to HIV infection. Cell 1996; 86: 36777.
  • 13
    Samson M, Libert F, Doranz BJ et al. Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 1996; 382: 7225.
  • 14
    Wang Y, Tao L, Mitchell E et al. Allo-immunization in women elicits CD8 suppressor factors, β-chemokines and resistance of CD4+ cells to HIV infection. Nature (Medicine) 1999; 5: 10049.
  • 15
    Endres MJ, Clapham PR, Marsh M et al. CD4-independent infection by HIV-2 is mediated by fusin/CXCR4. Cell 1996; 87: 74556.
  • 16
    Doyle CB, Bhattacharyya U, Kent KA et al. Regions required for CD4 binding in the external glycoprotein gp120 of simian immunodeficiency virus. J Virol 1995; 69: 125660.
  • 17
    Lehner T, Bergmeier L, Tao L et al. Targeted lymph node immunization with simian immunodeficiency virus p27 antigen to elicit genital, rectal and urinary immune responses in nonhuman primates. J Immunol 1994; 153: 185868.
  • 18
    Raport CJ, Gosling J, Schweickart VL et al. Molecular cloning and functional characterization of a novel human CC chemokine receptor (CCR5) for RANTES, MIP-1β and MIP-1α. J Biol Chem 1996; 271: 171616.
  • 19
    Bleul CC, Fuhlbrigge RC, Casanovas JM et al. A highly efficacious lymphocyte chemoattractant, stromal cell-derived factor 1 (SDF-1). J Exp Med 1996; 184: 11019.
  • 20
    Wang Y, Tao L, Mitchell E, Bergmeier L et al. The effect of immunization on chemokines and CCR5 and CXCR4 coreceptor functions in SIV binding and chemotaxis. Vaccine 1999; 17: 182636.DOI: 10.1016/s0264-410x(98)00482-4
  • 21
    Mackewicz CE, Levy JA. CD8+ cell anti-HIV activity: nonlytic suppresion of virus replication. AIDS Res Hum Retroviruses 1992; 8: 62940.
  • 22
    Lehner T, Wang Y, Cranage M et al. Protective mucosal immunity elicited by targeted iliac lymph node immunization with a subunit SIV envelope and core vaccine in macaques. Nat Med 1996; 2: 767 75.
  • 23
    Chen Z, Zhou P, Ho DD et al. Genetically divergent strains of simian immunodeficiency virus use CCR5 as a coreceptor for entry. J Virol 1997; 71: 270514.
  • 24
    Chackerian C, Lowy DR, Schiller JT. Induction of autoantibodies to mouse CCR5 with recombinant papillomavirus particles. Proc Natl Acad Sci USA 1999; 96: 23738.
  • 25
    Sallusto F, Lanzavecchia A. Understanding dendritic cell and T lymphocyte traffic through the analysis of chemokine receptor expression. Immunol Rev 2000; 177: 13440.
  • 26
    Lin H, Mossmann TR, Guilbert L et al. Synthesis of T helper 2-type cytokines at the maternal–fetal interface. J Immunol 1993; 151: 4562 73.
  • 27
    Wegmann TG, Lin H, Guilbert L, Mossmann TR. Bidirctional cytokine interactions in the maternal-fetal relationship: is successful pregnancy a TH2 phenomenon. Immunol Today 1994; 14: 3536.
  • 28
    Landay AL, Mackewicz CE, Levy JA. An activated CD8+ T cell phenotype correlates with anti-HIV activity and asymtomatic clinical status. Clin Immuno Immunopath 1993; 69: 10616.
  • 29
    Barker E, Bossart KN, Fujimura SH, Levy JA. CD28 costimulation increases CD8+ cell suspension of HIV replication. J Immunol 1997; 159: 512331.
  • 30
    Vila-Coro AJ, Mellado M, Martin de Ana A et al. HIV-1 infection through the CCR5 receptor is blocked by receptor dimerization. Proc Natl Acad Sci USA 2000; 97: 338893.
  • 31
    Lehner T, Shearer GM, Hackett CJ et al. Allo-immunization as a strategy for vaccine design against HIV/AIDS. AIDS Res Hum Retroviruses 2000; 116: 30913.